These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 15756435)

  • 21. Analysis of the HER2/neu gene amplification in microdissected breast cancer tumour samples.
    Seth RM; Burger AM; Kahn HJ
    Anticancer Res; 2006; 26(2A):927-31. PubMed ID: 16619488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The human breast cancer cell line IIB-BR-G has amplified c-myc and c-fos oncogenes in vitro and is spontaneously metastatic in vivo.
    Bover L; Barrio M; Bravo AI; Slavutsky I; Larripa I; Bolondi A; Ayala M; Mordoh J
    Cell Mol Biol (Noisy-le-grand); 1998 May; 44(3):493-504. PubMed ID: 9620446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.
    Park K; Kim J; Lim S; Han S; Lee JY
    Mod Pathol; 2003 Sep; 16(9):937-43. PubMed ID: 13679458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer.
    Stefano R; Agostara B; Calabrò M; Campisi I; Ravazzolo B; Traina A; Miele M; Castagnetta L
    Ann N Y Acad Sci; 2004 Dec; 1028():463-72. PubMed ID: 15650272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of HER2 overexpression in metastatic malignant melanoma.
    Inman JL; Kute T; White W; Pettenati M; Levine EA
    J Surg Oncol; 2003 Oct; 84(2):82-8. PubMed ID: 14502781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
    Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
    Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM; Murren JR; Rimm DL; King BL
    Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The candidate oncogene ZNF217 is frequently amplified in colon cancer.
    Rooney PH; Boonsong A; McFadyen MC; McLeod HL; Cassidy J; Curran S; Murray GI
    J Pathol; 2004 Nov; 204(3):282-8. PubMed ID: 15476264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Bhargava R; Lal P; Chen B
    Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE; Parkes RK; Andrulis I; O'Malley FP
    Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
    Shiu LY; Liang CH; Huang YS; Sheu HM; Kuo KW
    Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer.
    Szöllösi J; Balázs M; Feuerstein BG; Benz CC; Waldman FM
    Cancer Res; 1995 Nov; 55(22):5400-7. PubMed ID: 7585609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
    Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
    Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
    Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
    Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR gene and protein expression in breast cancers.
    Park K; Han S; Shin E; Kim HJ; Kim JY
    Eur J Surg Oncol; 2007 Oct; 33(8):956-60. PubMed ID: 17374474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2/neu amplification in breast cancer: stratification by tumor type and grade.
    Hoff ER; Tubbs RR; Myles JL; Procop GW
    Am J Clin Pathol; 2002 Jun; 117(6):916-21. PubMed ID: 12047143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization.
    Young SR; Liu WH; Brock JA; Smith ST
    Genes Chromosomes Cancer; 1996 Jun; 16(2):130-7. PubMed ID: 8818660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.